Clinical Trial

Genomically Guided Radiation Therapy in the Management of Triple Negative Breast Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of the study is to determine the feasibility of genomically guided radiation therapy (RT) in people with triple negative (HER2 negative, hormone receptor negative) breast cancer undergoing breast conservation therapy.
Protocol Amendment History 18 amendments
This ClinicalTrials.gov record has been amended 18 times since 2022-09-01; most recent amendment 2026-02-05.
Status change: Not Yet Recruiting → Recruiting 2022-11-01
Trial Details
NCT Number NCT05528133
Lead Sponsor H. Lee Moffitt Cancer Center and Research Institute
Conditions Triple Negative Breast Cancer
Enrollment 86 participants
Start Date 2023-01-25
Primary Completion 2028-05 (estimated)
Study Completion 2028-05 (estimated)
Updated on ClinicalTrials.gov 2026-02-09